Quiz

Quiz: Updated Guideline Recommendations for VMAT Inhibitor Use

07/29/2021

Popular Now

News

FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder

04/08/2024

Meagan Thistle

Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.

Ilperidone, already approved for...

04/08/2024

Psych Congress Network

News

Long-Acting Injectable Plus Cognitive Training Boosts Function in Early Schizophrenia

12/01/2020

Treatment with a long-acting injectable antipsychotic combined with cognitive training significantly improved cognitive deficits in patients after a first episode of schizophrenia, according to a study published online in Psychological...

Treatment with a long-acting...

12/01/2020

Psychiatry & Behavioral Health

Newsfeed

Sierra Tucson Chief Medical Officer Adds Same Title at Sonora Behavioral Health

06/20/2019

Aaron Wilson, MD, chief medical officer at Sierra Tucson has been named to the same position at another facility in the Acadia portfolio Sonora Behavioral Health Hospital.

Aaron Wilson, MD, chief medical...

06/20/2019

Addiction Professional

Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia

10/15/2020

Psychiatry & Behavioral Health

News

VMAT2 Inhibitor Shown to Improve Tardive Dyskinesia Symptoms

06/15/2021

SAN ANTONIO—Deutetrabenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, can improve symptoms of moderate to severe tardive dyskinesia (TD), posters presented at Psych Congress suggest. One poster outlined...

Quiz: Updated Guideline Recommendations for VMAT Inhibitor Use

Popular Now

Sign Up

Specialties

Events

Year Round Education

HMP Global Products